Research Training in Oncology

描述（由申请人提供）：这是塔夫茨医学中心William Dameshek血液学/肿瘤学分部的修订申请，用于竞争性更新我们长期的培训补助金T32 CA 09429，标题为“肿瘤学研究培训”。该申请的长期目标没有改变，即继续在基础和转化癌症科学的血液学/肿瘤学部门奖学金计划中培训和指导医生，以便为他们在学术血液学/肿瘤学方面的独立职业做好准备。该计划是基于血液学/肿瘤科在塔夫茨医学中心（塔夫茨MC），主要教学医院塔夫茨大学医学院（TUSM）。该培训计划是一个高度结构化的研究经验，围绕教师导师的研究小组内的实验室调查为中心。实验室部分是由正式的课程，其他教学培训，并参加研讨会，讲习班和会议的补充。每个学员的进步都受到一个研究委员会的密切监测。该计划目前有26名研究教师导师，来自该部门的成员以及塔夫茨MC和TUSM的其他临床和基础科学部门，比2002年最后一次竞争性更新的19名计划教师显着增加。这反映了塔夫茨MC和TUSM战略计划中对癌症的新重视，导致分子肿瘤学研究所的建立，以及为塔夫茨医学中心癌症中心获得国家癌症研究所综合癌症中心称号的重大机构努力。该计划的教师导师代表了应用程序的主要优势，并根据他们的培训记录和他们在肿瘤形成方面的具体研究兴趣精心挑选，这些研究兴趣涵盖了癌基因和肿瘤抑制因子，信号转导，细胞周期调控和凋亡，血管生成和转移，血液恶性肿瘤和实体瘤的动物模型，和分子靶向癌症治疗的临床前测试。这个培训计划在为我们的研究员在学术肿瘤学的职业生涯做准备方面非常成功。以前的学员现在领导学术界和NCI指定癌症中心的主要部门，在美国和其他地方的学术机构任教，并在肿瘤学制药领域担任高级管理职务。 相关性：在过去的十年里，通过开发特异性靶向癌细胞的药物，癌症的治疗发生了革命性的变化。美国非常需要癌症医生，他们在癌症患者和实验性治疗之间工作，并且能够发现和应用下一代疗法。这项拨款申请将支持塔夫茨医疗中心对这些医生的培训，继续实施一项在这一领域产生领导者超过四分之一世纪的计划。

DESCRIPTION (provided by applicant): This is a revised application from the William Dameshek Division of Hematology/Oncology at Tufts Medical Center for competitive renewal of our long-standing training grant, T32 CA09429, entitled "Research Training in Oncology". The long-term objective of the application has not changed, which is to continue the training and mentoring of physicians in the Hematology/Oncology Division Fellowship Program in basic and translational cancer science, in order to prepare them for independent careers in academic hematology/oncology. The program is based in the Division of Hematology/Oncology at Tufts Medical Center (Tufts MC), the principal teaching hospital for Tufts University School of Medicine (TUSM). The training program is a highly structured research experience that is centered around laboratory investigation within the research group of a faculty mentor. The laboratory component is complimented by formal coursework, other didactic training, and participation in seminars, workshops, and meetings. The progress of each trainee is closely monitored by a research committee. The Program currently has 26 research faculty mentors drawn from members of the Division and from other clinical and basic science departments at Tufts MC and TUSM, a significant increase from 19 Program faculty in the last competitive renewal in 2002. This reflects a new emphasis on cancer in the strategic plans of Tufts MC and TUSM, leading to the establishment of the Molecular Oncology Research Institute, and a major institutional effort to obtain National Cancer Institute Comprehensive Cancer Center designation for the Tufts Medical Center Cancer Center. The Program faculty mentors represent a major strength of the application, and are carefully selected on the basis of their training record and for their specific research interests in neoplasia, which span the spectrum from oncogenes and tumor suppressors, signal transduction, cell cycle regulation and apoptosis, angiogenesis and metastasis, animal models of hematologic malignancies and solid tumors, and preclinical testing of molecularly targeted cancer therapeutics. This training Program has been highly successful in preparing our fellows for careers in academic oncology. Former trainees now head major departments in academia and in NCI designated cancer centers, are on faculty at academic institutions in the US and elsewhere, and hold senior management positions in the oncology pharmaceutical field. RELEVANCE: The treatment of cancer has been revolutionized over the past ten years through the development of drugs that specifically target cancer cells. The United States has a great need for cancer doctors who work at the interface between cancer patients and experimental treatments, and who can discover and apply the next generation of therapies. This grant application will support the training of such physicians at Tufts Medical Center, continuing a program that has generated leaders in this field for more than a quarter century.